ATMI and Finesse Solutions sign distribution agreement

Will allow both companies to offer seamless support for single-use bioreactor systems

ATMI, a a leader in single-use process solutions, has signed a distribution agreement with Finesse Solutions, a manufacturer of measurement and control solutions for life sciences process applications.

The agreement will allow both companies to offer customers seamless support for single-use bioreactor systems enabled by the ATMI single-use Integrity PadReactor system and Finesse SmartSystems. The solution combines the optimised mixing and gas transfer performance of the space-efficient PadReactor bioreactor with the state-of-the-art TruFluor sensors for pH and dissolved oxygen and TruTorr sensors for pressure.

The integrated system couples the ATMI LifeScience Integrity PadReactor bioreactor with Finesse's G3-series SmartControllers and TruBio 4.X DV software, which are pre-configured for controlling process parameters such as pH, dissolved oxygen, temperature, agitation, gas/liquid flow and auxiliary analogue inputs/loops.

The integrated ATMI-Finesse bioreactor system can be purchased in a single transaction with follow-on application and technical support from both ATMI and Finesse. Under the terms of the agreement, Finesse will offer fully integrated turnkey systems for upstream bioprocessing. Additionally, ATMI will provide all post-point-of-sale customer requirements for PadReactor hardware and disposables while Finesse will support and service the controller, sensors and software.

The PadReactor system has an innovative, cube-shaped bioreactor vessel, which offers functionality that is comparable to or better than classical stirred-tank bioreactors

‘Based on the DeltaV control platform from Emerson, Finesse controllers allow users to scale their processes seamlessly from 1-litre lab-scale R&D bioreactors into cGMP single-use process trains having volumes up to 2,000 litres,’ said Finesse CEO Barbara Paldus. ‘By integrating our measurement and control solutions with the PadReactor system, Finesse will be able to offer a superior solution to its customer base for the production of recombinant proteins or vaccines.

‘The end results will include suspension cell configurations as well as the most effective and productive system for micro-carrier based processes in the industry.’

Global Director of Business Development for ATMI LifeSciences, Jeffery Craig, added, ‘The PadReactor system is specifically designed to meet the needs of cell culturists and is perfectly suited to process development, clinical material supply and flexible GMP manufacturing. It has an innovative, cube-shaped bioreactor vessel, which offers functionality that is comparable to or better than classical stirred-tank bioreactors. It also includes a single-use bag integrating an internal low-shear mixing paddle and sparger system.’

The PadReactor system is available in sizes ranging from 25 – 1,200 litres, and has been engineered to work in harmony with Finesse's cGMP-capable, highly configurable SmartSystems which features comprehensive functionality combined with easy process configuration and display.

Companies